Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $758.00 at Morgan Stanley

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price hoisted by Morgan Stanley from $730.00 to $758.00 in a research report released on Friday,Benzinga reports. They currently have an equal weight rating on the biopharmaceutical company’s stock.

A number of other research firms also recently issued reports on REGN. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. HSBC reduced their price objective on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Barclays lowered their target price on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Sanford C. Bernstein dropped their target price on Regeneron Pharmaceuticals from $925.00 to $921.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 8th. Finally, Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $900.00 to $700.00 in a report on Monday, May 18th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $794.83.

Regeneron Pharmaceuticals Stock Up 3.3%

NASDAQ:REGN opened at $762.63 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.29 and a quick ratio of 2.96. Regeneron Pharmaceuticals has a 1-year low of $541.00 and a 1-year high of $821.11. The company has a 50-day moving average of $643.13 and a 200 day moving average of $711.70. The firm has a market cap of $80.63 billion, a PE ratio of 18.85, a price-to-earnings-growth ratio of 29.50 and a beta of 0.24.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same quarter last year, the firm posted $12.81 EPS. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. As a group, research analysts anticipate that Regeneron Pharmaceuticals will post 2.06 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Insider Activity at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the completion of the sale, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of REGN. WPG Advisers LLC increased its position in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 25 shares in the last quarter. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at $26,000. Western Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth $26,000. Titan Wealth CI Ltd purchased a new position in Regeneron Pharmaceuticals during the 4th quarter worth $29,000. Finally, Kemnay Advisory Services Inc. purchased a new position in Regeneron Pharmaceuticals during the 4th quarter worth $31,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q2 results substantially exceeded expectations. Regeneron reported non-GAAP EPS of $14.29 versus the $10.16 consensus and revenue of $4.29 billion versus estimates of $3.82 billion. Revenue rose 16.7% year over year. Growth was led by record Dupixent sales, which increased 38%, and U.S. EYLEA HD sales, which jumped 52% to $596 million. Regeneron Q2 2026 Results
• Positive Sentiment: Several analysts raised their price targets after the report. Cantor Fitzgerald lifted its target to $795 and maintained an overweight rating, while Truist raised its target to $772 and reiterated buy. These targets imply additional upside based on the referenced current price. Analyst Price Target Updates
• Neutral Sentiment: Analyst sentiment remains mixed. Morgan Stanley raised its target to $758 and RBC to $737, but both maintained equal-weight or sector-perform ratings. Wells Fargo also raised its target to $750 while keeping an equal-weight rating, suggesting limited conviction despite the earnings beat. Analyst Price Target Updates
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The approximately 0.5% yield is modest and is unlikely to be a major stock catalyst.
• Negative Sentiment: Multiple law firms publicized a securities class action against Regeneron and its executives. The litigation alleges investors were misled about the protocol and prospects of the Phase 3 fianlimab-Libtayo melanoma trial, which ultimately failed and was associated with an approximately $11 billion market-cap loss. The September 14, 2026 lead-plaintiff deadline and continuing legal notices could pressure sentiment and create potential financial and reputational risks. Regeneron Securities Class Action

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.